. 2022 Jun 16;21(3):447–455. doi: 10.1007/s42000-022-00380-z

Table 4.

Characteristics of vaccine-associated subacute thyroiditis cases in the present study

No	Age/Sex	Vaccine type/dose	Post-vaccination sypmtom onset (days)	COVID-19 history*	Time to diagnosis (days)	Thyroid hormone status at diagnosis	Follow-up time (days)	Thyroid hormone status at follow-up	Treatment
1	71/F	CoronaVac®/1^st	4	No	20	O-Hyper	31	Euthyroid	MP
2	68/M	CoronaVac®^/2^nd	10	No	36	O-Hyper	57	S-Hypo	Ibuprofen
3	44/F	CoronaVac®/1^st	6	No	22	O-Hyper	42	Euthyroid	MP
4	62/M	CoronaVac®/1^st	6	Yes	19	O-Hyper	43	S-Hypo	Ibuprofen
5	32/F	Pfizer-BioNTech®/1^st	3	No	31	O-Hyper	93	Euthyroid	MP
6	39/F	CoronaVac®/2^nd	10	No	80	S-Hyper	59	Euthyroid	Ibuprofen
7	47/F	CoronaVac®/1^st	12	No	35	O-Hyper	48	Euthyroid	MP
8	45/F	Pfizer-BioNTech®/1^st	10	No	20	O-Hyper	49	Euthyroid	MP
9	43/F	Pfizer-BioNTech®/1^st	15	Yes	38	O-Hyper	35	Euthyroid	Ibuprofen
10	47/F	CoronaVac®/2^nd	20	Yes	60	S-Hyper	37	Euthyroid	Ibuprofen
11	48/M	CoronaVac®/1^st	6	No	30	S-Hyper	43	Euthyroid	Ibuprofen
12	67/M	Pfizer-BioNTech®/2^nd	2	No	18	O-Hyper	20	S-Hyper	MP
13	32/F	CoronaVac®/2^nd	6	No	25	O-Hyper	36	Euthyroid	MP
14	42/F	Pfizer-BioNTech®/1^st	2	No	27	S-Hyper	33	O-Hypo	Ibuprofen
15	53/F	CoronaVac®/2^nd	19	No	45	Euthyroid	35	Euthyroid	Ibuprofen
16	50/F	Pfizer-BioNTech®/1^st	7	No	90	O-Hyper	24	Euthyroid	Ibuprofen

MP methylprednisolone, S-Hyper subclinical hyperthyroidism, S-Hypo subclinical hypothyroidism, O-Hyper overt hyperthyroidism, O-Hypo overt hypothyroidism.^*Diagnosis of COVID-19 2 or more months prior to the diagnosis of subacute thyroiditis